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Nucleic acid molecules are championing a new generation of reverse engineered biopharmaceuticals. 
In terms of potential application in gene medicine, plasmid DNA (pDNA) vectors have exceptional 
therapeutic and immunological profiles as they are free from safety concerns associated with viral 
vectors, display non-toxicity and are simpler to develop. This review addresses the potential 
applications of pDNA molecules in vaccine design/development and gene therapy via recombinant DNA 
technology as well as a staged delivery mechanism for the introduction of plasmid-borne gene to target 
cells via the nasal route.  
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INTRODUCTION 
 
Recombinant DNA technology and the sequencing of the 
human genome have led to pertinent discoveries 
especially in the fields of gene therapy and nucleic acid 
vaccines. The DNA molecule is one of the most vital 
sources for the development of a novel group of 
therapeutics modelled on its endogenous structure (Wolf 
et al., 1990; Prather et al., 2003; Patil et al., 2005). DNA-
based therapeutics includes covalently closed circular 
plasmids containing transgenes for gene therapy, 
ribozymes, DNAzymes and oligonucleotides for antisense 
and antigene applications (Patil et al., 2005; Shroff et al., 
1999). Gene therapy processes involve the introduction 
of one or more functional and specific genes into a 
human recipient to repair certain genetic defects and 
aberrations. Plasmid DNA vaccine is developed from a 
pathogen’s gene to provide immunity against diseases by 
allowing the foreign genes to be expressed transiently in 
transfected cells, mimicking intracellular pathogenic 
infection and inducing both humoral and cellular immune 
responses (Gurunathan et al., 2000; Durland and 
Eastman, 1998). Plasmid DNA vaccines offer a platform 
to immunize with gene-based materials that are 
expressed by the cells of the recipient, and this provides 
a greater control over the immunisation process  because  
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the investigator determines which antigens and co-
stimulants to use, where to elicit the response, which 
cytokines to be co-expressed, amongst others (Prather et 
al., 2003; Durland and Eastman, 1998). Even though 
most of the plasmid-based therapeutic products are in the 
clinical trial stage, they have materialized lately to yield 
extremely promising candidates for drug therapy for 
many diseases such as influenza, cancer, AIDS, 
neurological and cardiovascular disorders (Patil et al., 
2005). One of the major merits of plasmid-based 
therapeutics over conventional low molecular weight 
pharmaceuticals is their specific selective identification of 
molecular targets and pathways leading to high specificity 
of action (Leitner et al., 2000; Mountain, 2000). Plasmid 
DNA uptake and metabolism considerably enhances the 
stability and minimizes the degradation of pDNA-based 
therapeutics. High molecular weight pDNA can effectively 
be delivered into cells using both synthetic and natural 
delivery systems (Donnelly et al., 1997; Davis, 2001). 
Besides enhancement in pharmacodynamics, pDNA 
delivery methodologies have achieved efficient targeted 
introduction of gene-based molecules into desired 
tissues. This article reviews the design and development 
of plasmid-based therapeutic products and their appli-
cations in gene therapy and genetic vaccination. A 
controlled nasal delivery mechanism for the introduction 
of plasmid-borne therapeutic genes to target cells, their 
uptake and improved pharmacokinetics/ 
pharmacodynamics. 
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Figure 1. A plasmid vector construct from the pUC family containing an ampicllin resistant gene, origin of replication, 
promoter, LacI repressor gene, LacZ gene for -peptide of -galactosidase and a multiple cloning region showing different 
restriction endocleases for sequence specific cleavages.  
 
 
 
PLASMID-BASED THERAPEUTIC PRODUCT DESIGN 
AND DEVELOPMENT 
 
The formulation and engineering of plasmids to obtain 
maximum transfection during therapeutic application is 
conceptually straightforward. Figure 1 shows a typical 
pUC-based pDNA construct. The pDNA should contain 
rudiments for maintenance and propagation in the 
bacterial host and for expression of the transgene in the 
human host. The elements required for bacterial 
propagation include the origin of replication and any 
plasmid-encoded functions such as RNAI and RNAII 
sequences required for replication (Ferber, 2001; Prather 
et al., 2003). Besides the transgene of interest, the pDNA 
molecules should contain regulatory indicators such as 
promoter and enhancer sequences for regulating gene 
expression. Promoters available for recombinant gene 
expressions in mammalian cells include those from 
human cytomegalovirus, simian virus, human elongation 
factor and human ubiquitin. Human promoters have 
greater resiliency against immune response activation 
than viral promoters. Enhancers are mainly tissue 
specific regions in the pDNA that enhance the production 
of the gene of interest and transcription efficiency (Patil et 
al., 2005; Gurunathan et al., 2000). An antibiotic resistant 
gene typically called selection marker should be included 
for the assortment of successful transformants upon 
initial introduction of the plasmid into the bacterial host 
and to create selective pressure against a prevalence of 
plasmid-free segregants arising in the population (Wolf et 
al., 1990; Patil et al., 2005). The choices that exist for the 
selectable marker can be categorised into two groups; 
those that require both plasmid and host-based genetic 
manipulations and those that require only plasmid-
encoded sequences (Patil et al., 2005; Prather et al., 
2003). During design of a plasmid vector suitable for 
therapeutic application, the regulatory environment must 
be considered. A key regulatory concern which is the 
possibility of pDNA integration should be addressed 
during the design of the plasmid. Promoters and 
terminator regions should also be carefully selected to 
restrict their biological activities on the sequences 
inserted on the plasmid. Possible adverse effects 
resulting from selection markers such as ototoxicity and 
nephrotoxicity must be considered in the choice of a 
selection marker. Kanamycin which is an amino glycoside 
antibiotic is known to be free from such concerns 
associated with -lactams (Wolf et al., 1990; Doolan and 
Hoffman, 2001; Patil et al., 2005).  
 
 
BIOPROCESS ENGINEERING OF PLASMID-BASED 
THERAPEUTIC PRODUCT 
 
Since Wolf and co-workers (1990) reported the uptake 
and extended in vivo expression of transgenes via 
injection of naked DNA into the leg muscle of mice, the 
use of pDNA molecules as vectors for gene therapy or 
vaccination has gained significant interest. Consequently, 
well in excess of hundred pDNA-based gene therapies, 
cancer vaccine and prophylactic vaccine clinical trials 
have been initiated (Shroff et al., 1999; Gurunathan et al., 
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Figure 2. Proposed process flow sheet for single-stage purification of plasmid-based therapeutic products (Danquah et al., 2008b).  
 
 
 
2000). This mass evolvement has yielded some early but 
encouraging results in the fight against some serious 
infectious diseases such as malaria (Doolan and 
Hoffman, 2001) and AIDS (Mascola and Nabel, 2001). 
However, although this novel vaccine technology appears 
very promising, it exhibits some limitations in the 
production of large quantities of pDNA to satisfy the 
growing market demands. At the laboratory scale, 
production and purification of plasmids are generally 
viewed as relatively easy and simple procedures. 
However, plasmid production under laboratory conditions 
generally leads to volumetric titers ranging from 5-40 
mg/L (Prazeres et al., 1999; Prather et al., 2003). In the 
context of milligram range doses and large patient 
populations, these processes and their associated 
productivity levels are inadequate for economically viable 
plasmid production. Although a few publications mention 
large-scale plasmid production processes achieving 
productivity levels of several hundreds of milligrams per 
litre (Lahijani et al., 1996; Chen et al., 1997; Schmidt et 
al., 2001; Carnes et al., 2006; Danquah and Forde, 
2008a), which represents a significant improvement over 
standard laboratory processes, it is likely that 
considerable room still exists for significant process 
improvements to be realized. The achievement of high-
volume pDNA manufacturing hinges on fermentation 
optimisation and a high throughput continuous 
purification methodology (Danquah and Forde, 2008a; 
Prather et al., 2003; Durland and Eastman, 1998). The 
process flow sheet in Figure 2 illustrates process 
development in the creation of an optimised fermentation 
scheme and a single-stage continuous purification step 
for pDNA product manufacturing with product purity and 
integrity meeting relevant regulatory standards. We have 
published elsewhere the performance of this technology 
in the creation of a rapid and economically-viable 
production platform for pDNA (Danquah and Forde, 2007; 
Danquah et al., 2008b). Table 1 shows data on current 
pDNA production levels.     
STAGED DELIVERY MECHANISM VIA THE NASAL 
ROUTE 
 
Currently,  pDNA  immunisation  can  be  achieved  using  
intramuscular/intradermal injection, gold particle bom-
bardment and needleless injection (Donnelly et al., 1997). 
These delivery methods are associated with some 
shortcomings thereby damping their effectiveness and 
immunological performance. Briefly, naked pDNA is 
unstable in biological fluid due to degradation by endo-
nuclease and low uptake by cells leading to reduced 
expression of the encoded gene. Therefore, the develop-
ment of a new and effective carrier system will be the key 
element to improve the potency of pDNA vaccines.  
The nasal route is an important arm of the mucosal and 
systemic immune system, since both humoral and 
cellular immune responses can occur (Davis, 2001). This 
revolutionary approach will overcome several of the 
problems of existing vaccine delivery including the need 
for medical personnel to administer needles, the cost and 
logistics of storing and transporting vaccines and hygienic 
needle use and disposal. Intranasal vaccination offer 
non-invasive administration and easily accessible for a 
larger population, thus, will greatly assist the develop-
ment of global health vaccination particularly in third 
world countries with the potential to reach greater 
numbers of people. Nasal delivery system can be 
achieved via different pharmaceutical forms such as dry 
powders, solutions or suspensions generated as different 
sized particles or droplets. The schematic pathways 
(Figure 3) in the nasal mucosa have been described by 
Kuper et al. (Kuper et al., 1992) where the particulate is 
taken up by the microfold epithelial cell, which is located 
in between the epithelial cells in lymphoid associated 
epithelium, and can elicit a local mucosal response or 
lead to a tolerance. The short residence time and low 
permeability of the formulations within the nasal cavity 
have contributed in poor bioavailability. The attention has 
therefore  shifted  to   the   evaluation   of   mucoadhesive  
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Table 1. Comparison of up-to-date top plasmid yields and productivity of various pilot-scale and industrial fermentation processes (Danquah and Forde, 2008a). 
 
 
Fermentation process 
 
Plasmid 
Biomass 
conc. (g/L) 
Yield 
(mg/L) 
Productivity 
(mg/Lh) 
Specific yield 
(mg/g) 
 
Reference 
Fed-batch (Pilot-scale) pUK21CMV 70.0 200 5.6 2.6 Schmidt et al., 2003  
Fed-batch (Pilot-scale) pSV 8.3 20 0.6 2.4 O' Kennedy et al., 2003  
Fed-batch (Pilot-scale) VCL1005G/A 38.8 218.6 11 5.6 Lahijani et al., 1996  
Fed batch NTC3019, 37oC (industrial-scale) pBR322 derived 60.5 438 13 7.2 Carnes et al., 2006 
Fed-batch (Pilot-scale) 37 - 42oC pUC19 10.8 529 22 49 Danquah and Forde, 2008 
Fed-batch NTC3019, 30 - 42oC (industrial scale) gWiz GFP 48.5 1070 26 22.1 Carnes et al., 2006 
Fed-batch NTC3019, 30 - 42oC (industrial-scale) pNTC7264-hmPA-EGFP 42.9 1497 36 34.9 Carnes et al., 2006 
 
Dry biomass concentration is estimated based on: 1.0 OD600 ≈ 0.5 g/L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Hypothetical pathway to elicit a local mucosa response via nasal mucosa. After 
the intranasal immunization, the biodegradable polymer particle is sampled by the 
microfold epithelial cell and the vaccine released in sustainable fashion. It is then passed 
on to underlying lymphoid cells in the submucosa for processing and presentation. This 
results in the activation of T-cells that help B-cells to develop into IgA plasma cells. 
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polymers that demonstrate additional permeation-
enhancing capabilities in nasal delivery (Ugwoke et al., 
2005). This is achieved by encapsulating the plasmid-
based therapeutic product into a mucoadhesive and 
biodegradable polymer system which is able to maintain 
sustained vaccine release over a period of time to 
specific sites. The biodegradable polymers can degrade 
in physiological environment, yielding naturally occurring 
metabolic products. Their degradation rate can be 
controlled to meet target usage such as staged delivery 
of vaccine. The method of staged delivery of plasmid–
borne gene vectors can help to optimise the 
pharmacokinetics and pharmacodynamics of the release 
mechanism.   
The design and use of biodegradable polymers for the 
controlled delivery of entrapped vaccines is an approach 
that holds promise for improving the duration and 
effectiveness of vaccine delivered locally or systema-
tically via nasal route. Toxicity due to spikes in vaccine 
concentration can also be reduced. On the other hand, 
the immune response associated with pDNA vaccine can 
be augmented using a protein booster in a prime-boost 
immunization system (Schultz et al., 2000). For instance, 
stronger humoral and cellular immune responses were 
elicited when immunised with a combined vaccine regime 
consisting of DNA prime encoding the HCV E2 and 
subsequently boosted with the respective recombinant 
protein (Song et al., 2000). Encapsulation of DNA-based 
prime and protein booster in different segments of 
biodegradable particulate system enable improved and 
homogenized overall immune response. 
 
 
CONCLUSION 
 
Plasmid DNA presents a novel alternative option for 
immunological disease control and prevention. With the 
recombinant DNA technology, one can re-design 
obsolete production and storage methods of conventional 
therapeutic techniques that have been ineffective in 
controlling certain diseases. By using pDNA, it is possible 
to address several diseases or disease strains in one 
vaccine, which will meet growing need for multivalent 
combination vaccines leading to fewer injections. Delivery 
of pDNA vectors harbouring therapeutic sequences via 
the nasal route also creates a good platform for 
staged/controlled delivery of transgenes to specific target 
cells. However, a greater body of clinical data and further 
enhancements in bioprocess engineering and delivery 
are required before pDNA products herald the new 
generation of therapeutics. 
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